Cecilia Ceresa1, Gabriella Nicolini1, Sara Semperboni1, Herwig Requardt2, Geraldine Le Duc2, Carlo Santini3, Maura Pellei3, Angela Bentivegna1, Leda Dalprà1, Guido Cavaletti4, Alberto Bravin2. 1. Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy. 2. Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF), Grenoble, France. 3. School of Science and Technology - Chemistry Division, University of Camerino, Camerino, Italy. 4. Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy cecilia.ceresa1@unimib.it.
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is one of the deadliest cancers characterized by very limited sensitivity to chemo- and/or radiotherapy. The presence of GBM stem-like cells in the tumor might be relevant for GBM treatment resistance. AIM: To provide a proof-of-concept of the efficacy of photon activation therapy (PAT) using monochromatic synchrotron radiation (SR), in killing GBM stem cells pre-treated with cisplatin. MATERIALS AND METHODS: Irradiation was performed using a 1-8 Gy dose range and energies just above or below the platinum K-shell edge (78.39 keV) or with a conventional X-ray source. Cells were exposed to drug concentrations allowing 90% cell survival, mimicking the unfavourable tissue distribution generally achieved in GMB patients. RESULTS: a significant enhancement in cell lethality was observed using SR compared to conventional X-ray irradiation. CONCLUSION: PAT deserved to be further explored in in vivo models based on GBM stem-like cells. Copyright
BACKGROUND:Glioblastoma multiforme (GBM) is one of the deadliest cancers characterized by very limited sensitivity to chemo- and/or radiotherapy. The presence of GBM stem-like cells in the tumor might be relevant for GBM treatment resistance. AIM: To provide a proof-of-concept of the efficacy of photon activation therapy (PAT) using monochromatic synchrotron radiation (SR), in killing GBM stem cells pre-treated with cisplatin. MATERIALS AND METHODS: Irradiation was performed using a 1-8 Gy dose range and energies just above or below the platinum K-shell edge (78.39 keV) or with a conventional X-ray source. Cells were exposed to drug concentrations allowing 90% cell survival, mimicking the unfavourable tissue distribution generally achieved in GMBpatients. RESULTS: a significant enhancement in cell lethality was observed using SR compared to conventional X-ray irradiation. CONCLUSION: PAT deserved to be further explored in in vivo models based on GBM stem-like cells. Copyright
Authors: Alessia Tudda; Elisabetta Donzelli; Gabriella Nicolini; Sara Semperboni; Mario Bossi; Guido Cavaletti; Roberta Castriconi; Paola Mangili; Antonella Del Vecchio; Antonio Sarno; Giovanni Mettivier; Paolo Russo Journal: Med Phys Date: 2021-12-01 Impact factor: 4.506